GUBRA Share Price Performance
DKK 379.80
-119.20 (-23.89%)
19.1% undervalued intrinsic discount
DKK 469.50
Fair Value
Price DKK 379.80
AnalystConsensusTarget DKK 469.50
Fair ValueDKK 469.50
Share Pricen/a
Gubra A/S Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
GUBRA Community Narratives
AN
Fair Value DKK 469.5 19.1% undervalued intrinsic discount
Specialized CRO Models Will Expand Drug Discovery Amid Uncertainty
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Specialized CRO Models Will Expand Drug Discovery Amid Uncertainty
Key Takeaways Expansion of proprietary peptide pipeline and major partnerships diversify revenue streams and enhance earnings resilience beyond core CRO services. Investments in advanced preclinical platforms and global reach position Gubra to capture a larger, higher-margin market as outsourcing in biotech grows.Read more
58
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
DKK 469.5
19.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-15.72% p.a.
Profit Margin
54.19%
Future PE
10.46x
Price in 2029
DKK 547.43
Trending Discussion
Recently Updated Narratives
AN
GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Fair Value: DKK 469.5 19.1% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Gubra A/S Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 20, 2026
- 103.51
- 96.96%
- 64.11%
- 0%
About GUBRA
- Founded
- 2008
- Employees
- 275
- CEO
- WebsiteView website
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus’ FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
